Actively Recruiting
Phase 2 Study of Camizestrant and Ribociclib Treatment in Adults With Hormone Receptor Positive Breast Cancer
Led by MedSIR · Updated on 2026-05-29
150
Participants Needed
16
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of combining ribociclib, a drug that inhibits certain proteins involved in cell growth, with camizestrant, a medication that blocks estrogen receptors, in treating advanced hormone receptor-positive breast cancer. This phase II study focuses on patients who have previously received hormone therapy for at least five years, including at least two years of aromatase inhibitor treatment. The main goal is to determine how long patients remain free from disease progression when treated with this combination. Participants will receive ribociclib orally at 600 mg daily for the first 21 days of each 28-day cycle, along with camizestrant taken orally at 75 mg every day throughout each 28-day cycle. The study includes an experimental treatment group receiving both drugs and a comparator group using historical data from previous clinical trials. This approach allows researchers to assess the combinations safety and effectiveness over time. During the study, participants will undergo regular assessments to monitor disease progression, response to treatment, and quality of life for up to 28 months. The research team will evaluate various outcomes such as progression-free survival, overall response rate, and patient-reported quality of life. Safety will also be closely monitored by tracking any adverse events. Participants are expected to attend scheduled visits for evaluations and provide tissue samples when available.
CONDITIONS
Brief Title
Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer
Research Team
M
MEDSIR
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here